Antibiotics (Oct 2022)

Tunisian Multicenter Study on the Prevalence of Colistin Resistance in Clinical Isolates of Gram Negative Bacilli: Emergence of <i>Escherichia coli</i> Harbouring the <i>mcr-1</i> Gene

  • Sana Ferjani,
  • Elaa Maamar,
  • Asma Ferjani,
  • Khaoula Meftah,
  • Hager Battikh,
  • Besma Mnif,
  • Manel Hamdoun,
  • Yosra Chebbi,
  • Lamia Kanzari,
  • Wafa Achour,
  • Olfa Bahri,
  • Adenene Hammami,
  • Meriam Zribi,
  • Hanen Smaoui,
  • Ilhem Boutiba-Ben Boubaker

DOI
https://doi.org/10.3390/antibiotics11101390
Journal volume & issue
Vol. 11, no. 10
p. 1390

Abstract

Read online

Background: Actually, no data on the prevalence of plasmid colistin resistance in Tunisia are available among clinical bacteria. Objectives: This study aimed to investigate the current epidemiology of colistin resistance and the spread of the mcr gene in clinical Gram-negative bacteria (GNB) isolated from six Tunisian university hospitals. Methods: A total of 836 GNB strains were inoculated on COL-R agar plates with selective screening agar for the isolation of GNB resistant to colistin. For the selected isolates, mcr genes, beta-lactamases associated-resistance genes and molecular characterisation were screened by PCRs and sequencing. Results: Colistin-resistance was detected in 5.02% (42/836) of the isolates and colistin-resistant isolates harboured an ESBL (blaCTX-M-15) and/or a carbapenemase (blaOXA-48, blaVIM) encoding gene in 45.2% of the cases. The mcr-1 gene was detected in four E. coli isolates (0.59%) causing urinary tract infections and all these isolates also contained the blaTEM-1 gene. The blaCTX-M-15 gene was detected in three isolates that also carried the IncY and IncFIB replicons. The genetic environment surrounding the mcr-carrying plasmid indicated the presence of pap-2 gene upstream mcr-1 resistance marker with unusual missing of ISApl1 insertion sequence. The Conclusions: This study reports the first description of the mcr-1 gene among clinical E. coli isolates in Tunisia and provides an incentive to conduct routine colistin susceptibility testing in GNB clinical isolates.

Keywords